# SS-31 elamipretide eye drops for LHON: phase II trial

Source: https://pepvault.app/research/ss-31-karanjia-2024

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [SS-31](https://pepvault.app/research#ss-31)

Randomized trial · people

# SS-31 (elamipretide) eye drops missed main vision goal in LHON trial

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In this small trial, elamipretide eye drops looked safe for people with LHON but did not improve sharpness of vision, and the hints of benefit on other vision tests still need confirming.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 12
- **Published:** 2024
- **Journal:** Ophthalmology

## What they tested

The team tested whether elamipretide eye drops are safe in people with Leber hereditary optic neuropathy (LHON, an inherited condition that causes vision loss) and whether they improve vision.

## How the study was done

A phase II, randomized, double-masked trial at 1 center in 12 adults aged 18 to 50 with a genetically confirmed form of LHON and vision loss lasting 1 to 10 years. For 52 weeks, people got elamipretide 1% drops in both eyes or in 1 eye with vehicle (drops without the drug) in the other, then all eyes got elamipretide in an open-label extension, where everyone knew the treatment, for up to 108 more weeks.

<!--promo-->

PepVault for iPhone

## Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

Elamipretide was well tolerated, most side effects were mild to moderate and went away on their own, and there were no serious side effects. Change in best-corrected visual acuity (sharpest vision with glasses or lenses) did not differ between elamipretide eyes and vehicle eyes at any time point, so the trial missed its main efficacy goal. Six of 12 people met the trial's criteria for a clinically relevant benefit. In a post hoc analysis, central visual field mean deviation improved more in elamipretide eyes than vehicle eyes, and color discrimination and contrast sensitivity improved from baseline during the open-label extension.

## What it doesn’t show

This was a very small, single-center trial in 1 genetic form of LHON. The visual field result came from an analysis planned after the fact, and the gains in the open-label extension had no vehicle comparison.

## The paper

Karanjia and Sadun Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial. Ophthalmology. 2024.

- [PubMed (PMID 37923251)](https://pubmed.ncbi.nlm.nih.gov/37923251/)
- [The paper (DOI 10.1016/j.ophtha.2023.10.033)](https://doi.org/10.1016/j.ophtha.2023.10.033)

## The compound

- [SS-31: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

## With this study

### SS-31

- [SS-31: the full reference](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-10mg)
- [50 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-50mg)

### Studies

- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023)
- [SS-31: no 12-week benefit, walk gains by 36 weeks open-label](https://pepvault.app/research/ss-31-reid-thompson-2021)
- [All 12 studies](https://pepvault.app/research#ss-31)

### Compared with

- [MOTS-c vs SS-31](https://pepvault.app/peptides/compare/mots-c-vs-ss-31)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

## More studies on SS-31

- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023) Randomized trial · people · 2023
- [SS-31: no 12-week benefit, walk gains by 36 weeks open-label](https://pepvault.app/research/ss-31-reid-thompson-2021) Randomized trial · people · 2021
- [SS-31 raised muscle ATP capacity after one dose in older adults](https://pepvault.app/research/ss-31-roshanravan-2021) Randomized trial · people · 2021
- [SS-31: walk distance rose with dose in 5-day MMPOWER trial](https://pepvault.app/research/ss-31-mmpower-2018) Randomized trial · people · 2018
- [SS-31: less kidney hypoxia after renal artery stenting in pilot](https://pepvault.app/research/ss-31-saad-2017) Randomized trial · people · 2017
- [SS-31 did not significantly cut infarct size in EMBRACE STEMI](https://pepvault.app/research/ss-31-embrace-stemi-2016) Randomized trial · people · 2016
- [Every study on SS-31](https://pepvault.app/research#ss-31)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### SS-31

- [SS-31: the full reference](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-10mg)
- [50 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-50mg)

### Studies

- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023)
- [SS-31: no 12-week benefit, walk gains by 36 weeks open-label](https://pepvault.app/research/ss-31-reid-thompson-2021)
- [All 12 studies](https://pepvault.app/research#ss-31)

### Compared with

- [MOTS-c vs SS-31](https://pepvault.app/peptides/compare/mots-c-vs-ss-31)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

<!--promo-->

PepVault for iPhone

## Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on SS-31](https://pepvault.app/research#ss-31)

## The library

- [SS-31](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
